ATE210649T1 - Arylacrylamidderivate als 5ht1 agoniste oder antagoniste - Google Patents

Arylacrylamidderivate als 5ht1 agoniste oder antagoniste

Info

Publication number
ATE210649T1
ATE210649T1 AT97302995T AT97302995T ATE210649T1 AT E210649 T1 ATE210649 T1 AT E210649T1 AT 97302995 T AT97302995 T AT 97302995T AT 97302995 T AT97302995 T AT 97302995T AT E210649 T1 ATE210649 T1 AT E210649T1
Authority
AT
Austria
Prior art keywords
agonists
antagonists
arylacrylamide
derivatives
arylacrylamide derivatives
Prior art date
Application number
AT97302995T
Other languages
English (en)
Inventor
Harry Ralph Howard
Barbara Eileen Segelstein
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE210649T1 publication Critical patent/ATE210649T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, ***e
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97302995T 1996-05-28 1997-05-01 Arylacrylamidderivate als 5ht1 agoniste oder antagoniste ATE210649T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1858096P 1996-05-28 1996-05-28

Publications (1)

Publication Number Publication Date
ATE210649T1 true ATE210649T1 (de) 2001-12-15

Family

ID=21788674

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97302995T ATE210649T1 (de) 1996-05-28 1997-05-01 Arylacrylamidderivate als 5ht1 agoniste oder antagoniste

Country Status (9)

Country Link
US (1) US6258953B1 (de)
EP (1) EP0810220B1 (de)
JP (1) JP3026948B2 (de)
AT (1) ATE210649T1 (de)
CA (1) CA2206122C (de)
DE (1) DE69708968T2 (de)
DK (1) DK0810220T3 (de)
ES (1) ES2166046T3 (de)
PT (1) PT810220E (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
ATE273970T1 (de) 1998-04-16 2004-09-15 Pfizer Prod Inc N-acyl und n-aroyl aralkylamide
PE20000942A1 (es) * 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
CA2448894A1 (en) * 2001-05-31 2002-12-05 Bristol-Myers Squibb Company Cinnamide derivatives as kcnq potassium channel modulators
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7045551B2 (en) 2002-11-22 2006-05-16 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
WO2004047744A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company 3-heterocyclic benzylamide derivatives as potassium channel openers
EP1572112A4 (de) 2002-11-22 2006-12-06 Bristol Myers Squibb Co 3-(pyridinyl-piperazin-1-yl)-phenylethylamide alskaliumkanalöffner
AU2003295782A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
WO2004047738A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company Arylcyclopropylcarboxylic amides as potassium channel openers
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10360745A1 (de) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20050171095A1 (en) * 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
JP2007537151A (ja) * 2004-01-29 2007-12-20 ファイザー・プロダクツ・インク γ−アミノ酪酸モジュレータと5−HT1B受容体アンタゴニストとの組合せ
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
CN102515996B (zh) * 2011-11-14 2015-11-25 南开大学 一种合成β-芳基丙烯酰胺类化合物的方法
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
WO2018112077A1 (en) * 2016-12-13 2018-06-21 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4564685A (en) * 1983-03-10 1986-01-14 Findlay John W A Diphenylmethane compounds
DK0689536T3 (da) * 1993-03-16 2001-07-30 Pfizer Naphthalenderivater

Also Published As

Publication number Publication date
ES2166046T3 (es) 2002-04-01
JPH1095765A (ja) 1998-04-14
DE69708968D1 (de) 2002-01-24
EP0810220A1 (de) 1997-12-03
EP0810220B1 (de) 2001-12-12
CA2206122C (en) 2002-03-05
DK0810220T3 (da) 2002-03-18
PT810220E (pt) 2002-04-29
JP3026948B2 (ja) 2000-03-27
DE69708968T2 (de) 2002-04-25
US6258953B1 (en) 2001-07-10
CA2206122A1 (en) 1997-11-28
MX9703899A (es) 1998-06-30

Similar Documents

Publication Publication Date Title
ATE210649T1 (de) Arylacrylamidderivate als 5ht1 agoniste oder antagoniste
DE69628804D1 (de) Substitutierte heterozyclische Derivate als CRF Antagonisten
ES2188095T3 (es) Carboxamidas heterociclicas.
ID18883A (id) Pesaing 5-ht 1f
ATE168992T1 (de) 7-substituierte-9-substituierte glycylamido-6- demethyl-6-deoxytetracycline
ES2182234T3 (es) Inhibidores de metaloproteasa.
ATE163648T1 (de) Indole derivate als serotonin-antagonisten
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
DK1109817T3 (da) Phosphohalogenhydriner, deres fremstilling og anvendelse
FI902555A0 (fi) Diarylstyrylkinolindisyror.
DE60121461D1 (de) Kondensierte pyridoindolderivate
ATE177096T1 (de) 4-substituierte 1,2,4-triazolderivate
FI900041A0 (fi) Substituerade indol-, benzofuran- och benzotiopenderivat saosom 5-lipoxigenasinhibitorer,
PT952154E (pt) N-acil- e n-aroil-aralquilamidas
ID23053A (id) Karboksamida yang digunakan sebagai agonis 5-ht <if>
DE60112960D1 (de) Kondensierte pyridoindolderivate
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
FI965238A0 (fi) Aryyli- ja heteroaryylialkoksinaftaleenijohdannaiset
ITMI930819A1 (it) Derivati eterobiciclici ad attivita' fungicida
PT1140932E (pt) Derivados de 1,8-benzonaftiridina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee